[September 20, 2017] |
|
PureTech Health Notes U.S. Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech
PureTech Health plc ("PureTech Health" or the "Company", LSE: PRTC), an
advanced, clinical-stage biopharmaceutical company, is pleased to note
that the United States Patent and Trademark Office (USPTO) has issued
U.S. Patent No. 9,763,617 for its Sonde vocal biomarkers program. The
patent broadly covers methods of assessing a mental or physical
condition of a subject, using phonetic structures, or phones, extracted
from speech audio waveforms. The issued patent is exclusively licensed
under an agreement with the Massachusetts Institute of Technology (MIT (News - Alert))
and provides coverage through at least 2032.
"This newly issued patent represents, to the best of our knowledge, the
only coverage for novel vocal biomarkers that have been demonstrated to
enhance vocal analysis performance for assessment of a broad range of
diseases," said Jim Harper, Ph.D., PureTech Health Vocal Biomarker
Program Lead. "Issuance of this patent strengthens our leading
intellectual property portfolio in the emerging field of acoustic voice
analysis for health, and it provides validation of our novel vocal
biomarkers technology for the assessment of mental and physical
conditions."
The patented technology, created by a team at MIT Lincoln Laboratory (News - Alert) led
by Thomas Quatieri, Ph.D., enables analysis of subtle - yet quantifiable
- changes in the voice to improve automated measures of important
aspects of an individual's health. Pilot studies using the exclusively
licensed technology have also demonstrated the potential to detect and
objectively measure symptoms in a range of important conditions
including depression, mild traumatic brain injury (mTBI), concussion,
cognitive impairment and Parkinson's Disease. The vocal biomarkers
program (Sonde) has been integrating and extending this technology for
analysis of an individual's voice on commonly-owned devices. Testing of
the Sonde technology in over a thousand subjects has demontrated the
potential to effectively screen and monitor for disease using only a few
seconds of voice. The Sonde technology is being developed to enable
disease-associated features of speech to be measured without capturing
the contents of speech, therefore protecting privacy.
About PureTech Health PureTech Health (PureTech Health
plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company
developing novel medicines targeting serious diseases that result from
dysfunctions in the nervous, immune, and gastrointestinal systems
(brain-immune-gut or the "BIG" axis), which together represent the
adaptive human systems. PureTech Health is at the forefront of
understanding and addressing the biological processes and crosstalk
associated with the BIG axis. By harnessing this emerging field of human
biology, the Company is pioneering new categories of medicine with the
potential to have great impact on people with serious diseases. PureTech
Health is advancing a rich pipeline of innovative therapies that
includes two pivotal or registration studies expected to read out in
2017, multiple human proof-of-concept studies and a number of early
clinical and pre-clinical programs. PureTech's rich research and
development pipeline has been advanced in collaboration with some of the
world's leading scientific experts, who along with PureTech's team of
biopharma pioneers, entrepreneurs and seasoned Board, identify, invent,
and clinically de-risk new medicines. With this experienced team
pursuing cutting edge science, PureTech Health is building the biopharma
company of the future focused on improving and extending the lives of
people with serious disease. For more information, visit www.puretechhealth.com
or connect with us on Twitter (News - Alert) @puretechh.
Forward Looking Statement This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations, including,
but not limited to, those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events or
otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170919006729/en/
[ Back To TMCnet.com's Homepage ]
|